Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lipocine Inc | LPCN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.90 | 06:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.90 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.3101 - 7.15 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 6.90 | USD |
Lipocine Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 36.68M | 5.32M | - | -2.85M | -16.35M | -3.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lipocine News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/03/2024 | 16:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/03/2024 | 16:09 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 5/09/2024 | 07:00 | PR Newswire (US) | Lipocine Announces Financial Results for the First Quarter.. |
| 5/09/2024 | 05:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/09/2024 | 05:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/08/2024 | 07:00 | PR Newswire (US) | Lipocine Announces Late Breaking Oral Presentation of Data.. |
| 5/08/2024 | 05:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/01/2024 | 07:00 | PR Newswire (US) | Lipocine Announces Completion of Dosing in Pivotal Study of.. |
| 4/11/2024 | 06:00 | PR Newswire (US) | Lipocine Announces Positive LPCN 2401 Clinical Results.. |
| 3/28/2024 | 07:00 | PR Newswire (US) | Lipocine Announces Positive Week 52 Results from LPCN 1148.. |
| 3/25/2024 | 07:00 | PR Newswire (US) | Lipocine Announces First Cohort Dosed in Pivotal Study of.. |
| 3/07/2024 | 16:31 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LPCN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.76 | 7.12 | 6.5001 | 6.79 | 24,477 | 0.14 | 2.07% |
| 1 Month | 5.03 | 7.12 | 4.80 | 6.05 | 27,930 | 1.87 | 37.18% |
| 3 Months | 3.57 | 7.15 | 3.31 | 5.85 | 73,029 | 3.33 | 93.28% |
| 6 Months | 2.61 | 7.15 | 2.40 | 5.22 | 47,243 | 4.29 | 164.37% |
| 1 Year | 4.50 | 7.15 | 2.3101 | 4.96 | 70,023 | 2.40 | 53.33% |
| 3 Years | 19.72 | 32.13 | 2.3101 | 17.81 | 337,644 | -12.82 | -65.01% |
| 5 Years | 25.67 | 59.50 | 2.3101 | 23.40 | 986,765 | -18.77 | -73.12% |
Lipocine Description
| Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other products in the pipeline such as LPCN 1144 LPCN 1148 and LPCN 1107. |
